CRISPR Therapeutics AG (CRSP)

72.15 +0.41 (+0.57%) At close: 04:00PM EDT

CRISPR Therapeutics AG

Baarerstrasse 14
Zug 6300
Switzerland
41 41 561 32 77
https://www.crisprtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 473

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Samarth Kulkarni Ph.D.	CEO & Director	1.26M	15.55M	1979
Mr. Brendan Smith M.B.A.	Sr. VP, CFO & Principal Accounting Officer	222.61k	N/A	1976
Dr. Lawrence Otto Klein Ph.D.	Chief Operating Officer	734.98k	13.44M	1983
Mr. James R. Kasinger	Gen. Counsel & Sec.	666.1k	4.53M	1972
Dr. Rodger Novak M.D.	Founder, Chairman & Pres	N/A	N/A	1967
Mr. Shaun Foy	Founder	N/A	N/A	N/A
Dr. Emmanuelle Marie Charpentier	Co-Founder & Scientific Advisory Board Member	N/A	N/A	N/A
Dr. Craig C. Mello Ph.D.	Scientific Founder & Advisory Board Member	N/A	N/A	N/A
Dr. Chad A. Cowan Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Matthew Porteus M.D., Ph.D.	Scientific Founder & Advisory Board Member	N/A	N/A	1965

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Corporate Governance

CRISPR Therapeutics AG’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.